Donor derived Faecal Microbiota Transplantation (FMT) is  a highly effective therapy for the treatment of C.difficle infection; the most common cause of health care associated diarrhoea. Multiple randomised controlled trials and meta-analyses of these studies have demonstrated the superiority of FMT over antibiotic therapy alone for the treatment of recurrent C.difficile infection.

While FMT is now the standard of care for recurrent C.difficile infection in most international guidelines, evidence is emerging for its use in other diseases. BiomeBank’s co-founders Dr Sam Costello and Dr Rob Bryant have been pioneers in this field and BiomeBank is facilitating a number of clinical trials in a range of diseases with collaborating organisations.